FDA Approves Expansion of Modulators for People With Certain Rare Mutations
December 21, 2020
The U.S. Food and Drug Administration today expanded its approval of three CFTR modulators to include additional people with CF who have certain rare mutations. The approval enables more than 600 individuals with CF who were not previously eligible for modulators to access drugs that treat the underlying cause of their disease for the first time.